Manipulating IL-2 and IL-2R in autoimmune diseases and transplantation

Flavio Vincenti, Robert Kirkman, Susan Light, Ginny Bumgardner, Mark Pescovitz, Philip Halloran, John Neylan, Alan Wilkinson, Henrik Ekberg, Robert Gaston, Lars Backman, James Burdick, Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation New England Journal of Medicine. ,vol. 338, pp. 161- 165 ,(1998) , 10.1056/NEJM199801153380304

Daniel T. Patton, Oliver A. Garden, Wayne P. Pearce, Louise E. Clough, Clare R. Monk, Eva Leung, Wendy C. Rowan, Sara Sancho, Lucy S. K. Walker, Bart Vanhaesebroeck, Klaus Okkenhaug, Cutting edge: The phosphoinositide 3-kinase p110 delta is critical for the function of CD4(+)CD25(+)Foxp3(+) regulatory T cells Journal of Immunology. ,vol. 177, pp. 6598- 6602 ,(2006) , 10.4049/JIMMUNOL.177.10.6598

Jayne F Martin, Justin SA Perry, Neha R Jakhete, Xiang Wang, Bibiana Bielekova, None, An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2–Driven Activation of CD56bright NK Cells The Journal of Immunology. ,vol. 185, pp. 1311- 1320 ,(2010) , 10.4049/JIMMUNOL.0902238

Ashley E. Mahne, Joanna E. Klementowicz, Annie Chou, Vinh Nguyen, Qizhi Tang, Therapeutic Regulatory T Cells Subvert Effector T Cell Function in Inflamed Islets To Halt Autoimmune Diabetes Journal of Immunology. ,vol. 194, pp. 3147- 3155 ,(2015) , 10.4049/JIMMUNOL.1402739

Jamie B Spangler, Jakub Tomala, Vincent C Luca, Kevin M Jude, Shen Dong, Aaron M Ring, Petra Votavova, Marion Pepper, Marek Kovar, K Christopher Garcia, None, Antibodies to Interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms Immunity. ,vol. 42, pp. 815- 825 ,(2015) , 10.1016/J.IMMUNI.2015.04.015

David Klatzmann, Abul K. Abbas, The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases Nature Reviews Immunology. ,vol. 15, pp. 283- 294 ,(2015) , 10.1038/NRI3823

Thomas R. Malek, Iris Castro, Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity Immunity. ,vol. 33, pp. 153- 165 ,(2010) , 10.1016/J.IMMUNI.2010.08.004

Björn Nashan, Richard Moore, Peter Amlot, Albrecht-Georg Schmidt, Kamal Abeywickrama, Jean-Paul Soulillou, Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients The Lancet. ,vol. 350, pp. 1193- 1198 ,(1997) , 10.1016/S0140-6736(97)09278-7

Frédéric Van Gool, Ari B. Molofsky, Malika M. Morar, Michelle Rosenzwajg, Hong-Erh Liang, David Klatzmann, Richard M. Locksley, Jeffrey A. Bluestone, Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. Blood. ,vol. 124, pp. 3572- 3576 ,(2014) , 10.1182/BLOOD-2014-07-587493

Zhi-Zhang Yang, Deanna M. Grote, Steven C. Ziesmer, Michelle K. Manske, Thomas E. Witzig, Anne J. Novak, Stephen M. Ansell, Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood. ,vol. 118, pp. 2809- 2820 ,(2011) , 10.1182/BLOOD-2011-03-340885